Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $51,386 | 13 | 71.4% |
| Honoraria | $8,508 | 4 | 11.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,922 | 2 | 8.2% |
| Travel and Lodging | $4,315 | 19 | 6.0% |
| Food and Beverage | $1,151 | 18 | 1.6% |
| Unspecified | $525.00 | 1 | 0.7% |
| Education | $149.00 | 3 | 0.2% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | $30,476 | 6 | $0 (2024) |
| Blueprint Medicines Corporation | $9,547 | 14 | $0 (2024) |
| AbbVie Inc. | $8,826 | 13 | $0 (2023) |
| Illumina, Inc. | $5,973 | 3 | $0 (2024) |
| Acceleron Pharma, Inc. | $5,490 | 1 | $0 (2020) |
| E.R. Squibb & Sons, L.L.C. | $3,717 | 6 | $0 (2019) |
| Eli Lilly and Company | $2,468 | 2 | $0 (2019) |
| Genentech, Inc. | $1,695 | 1 | $0 (2022) |
| Daiichi Sankyo Inc. | $1,665 | 1 | $0 (2023) |
| Agilent Technologies, Inc. | $1,145 | 4 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $12,465 | 12 | Blueprint Medicines Corporation ($5,702) |
| 2023 | $14,991 | 7 | Vertex Pharmaceuticals Incorporated ($8,542) |
| 2022 | $23,619 | 10 | Vertex Pharmaceuticals Incorporated ($18,256) |
| 2021 | $90.50 | 2 | Blueprint Medicines Corporation ($90.50) |
| 2020 | $5,490 | 1 | Acceleron Pharma, Inc. ($5,490) |
| 2019 | $6,279 | 9 | E.R. Squibb & Sons, L.L.C. ($3,717) |
| 2018 | $720.78 | 7 | Abbott Laboratories ($720.78) |
| 2017 | $8,301 | 12 | AbbVie, Inc. ($8,301) |
All Payment Transactions
60 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | Illumina, Inc. | Genetic Disease Research (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,946.00 | General |
| Category: Genetics | ||||||
| 12/12/2024 | Blueprint Medicines Corporation | — | Travel and Lodging | In-kind items and services | $382.94 | General |
| 12/12/2024 | Blueprint Medicines Corporation | — | Travel and Lodging | In-kind items and services | $80.00 | General |
| 12/03/2024 | Blueprint Medicines Corporation | — | Honoraria | Cash or cash equivalent | $4,312.00 | General |
| 12/03/2024 | Blueprint Medicines Corporation | — | Travel and Lodging | Cash or cash equivalent | $137.48 | General |
| 12/03/2024 | Blueprint Medicines Corporation | — | Food and Beverage | Cash or cash equivalent | $38.77 | General |
| 11/19/2024 | Blueprint Medicines Corporation | — | Travel and Lodging | In-kind items and services | $360.47 | General |
| 11/19/2024 | Blueprint Medicines Corporation | — | Travel and Lodging | In-kind items and services | $279.97 | General |
| 11/19/2024 | Blueprint Medicines Corporation | — | Travel and Lodging | In-kind items and services | $80.00 | General |
| 11/15/2024 | Blueprint Medicines Corporation | — | Food and Beverage | In-kind items and services | $29.87 | General |
| 09/09/2024 | Beckman Coulter, Inc. | — | Food and Beverage | In-kind items and services | $139.13 | General |
| 01/10/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Consulting Fee | Cash or cash equivalent | $3,677.96 | General |
| 12/07/2023 | Illumina, Inc. | Oncology Testing (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,976.00 | General |
| Category: Genetics | ||||||
| 12/07/2023 | Illumina, Inc. | Oncology Testing (Device) | Travel and Lodging | In-kind items and services | $50.83 | General |
| Category: Genetics | ||||||
| 10/25/2023 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $1,665.00 | General |
| 07/25/2023 | Blueprint Medicines Corporation | — | Honoraria | Cash or cash equivalent | $1,232.00 | General |
| 06/21/2023 | Vertex Pharmaceuticals Incorporated | — | Consulting Fee | Cash or cash equivalent | $3,166.67 | General |
| 04/27/2023 | AbbVie Inc. | VENCLEXTA (Drug) | — | Cash or cash equivalent | $525.00 | Research |
| Study: Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome (Verona) • Category: ONCOLOGY | ||||||
| 01/04/2023 | Vertex Pharmaceuticals Incorporated | — | Consulting Fee | Cash or cash equivalent | $5,375.00 | General |
| 11/01/2022 | Agilent Technologies, Inc. | — | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| 11/01/2022 | Agilent Technologies, Inc. | — | Honoraria | Cash or cash equivalent | $500.00 | General |
| 11/01/2022 | Agilent Technologies, Inc. | — | Food and Beverage | In-kind items and services | $125.00 | General |
| 11/01/2022 | Agilent Technologies, Inc. | — | Travel and Lodging | In-kind items and services | $20.00 | General |
| 10/21/2022 | Blueprint Medicines Corporation | — | Honoraria | Cash or cash equivalent | $2,464.00 | General |
| 09/26/2022 | Blueprint Medicines Corporation | — | Education | In-kind items and services | $58.50 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome (Verona) | AbbVie Inc. | $525.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 1,222 | 2,128 | $332,690 | $54,208 |
| 2022 | 15 | 1,154 | 2,078 | $334,040 | $54,887 |
| 2021 | 16 | 1,212 | 1,987 | $318,232 | $54,353 |
| 2020 | 16 | 1,304 | 1,944 | $300,500 | $54,169 |
All Medicare Procedures & Services
62 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 88189 | Flow cytometry technique for dna or cell analysis, 16 or more markers | Facility | 2023 | 137 | 146 | $54,750 | $9,499 | 17.3% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Facility | 2023 | 143 | 293 | $67,390 | $8,370 | 12.4% |
| 88341 | Special stained specimen slides to examine tissue, each additional procedure | Facility | 2023 | 70 | 295 | $39,825 | $6,496 | 16.3% |
| 88319 | Evaluation of specimen enzymes | Facility | 2023 | 137 | 307 | $27,630 | $6,324 | 22.9% |
| 85097 | Bone marrow, smear interpretation | Facility | 2023 | 135 | 143 | $39,325 | $5,285 | 13.4% |
| 88360 | Microscopic genetic analysis of tumor, manual | Facility | 2023 | 79 | 144 | $28,800 | $4,679 | 16.2% |
| 88313 | Special stained specimen slides to examine tissue including interpretation and report | Facility | 2023 | 137 | 394 | $19,700 | $3,674 | 18.7% |
| 88342 | Special stained specimen slides to examine tissue, initial procedure | Facility | 2023 | 89 | 93 | $13,950 | $2,524 | 18.1% |
| 88188 | Flow cytometry technique for dna or cell analysis, 9 to 15 markers | Facility | 2023 | 46 | 51 | $14,280 | $2,392 | 16.7% |
| 88311 | Preparation of tissue for examination by removing any calcium present | Facility | 2023 | 140 | 148 | $6,660 | $1,421 | 21.3% |
| 88307 | Pathology examination of tissue using a microscope, moderately high complexity | Facility | 2023 | 20 | 22 | $6,820 | $1,411 | 20.7% |
| 85060 | Blood smear interpretation by physician with written report | Facility | 2023 | 49 | 52 | $3,900 | $988.52 | 25.3% |
| 88187 | Flow cytometry technique for dna or cell analysis, 2 to 8 markers | Facility | 2023 | 18 | 18 | $4,050 | $503.10 | 12.4% |
| 88368 | Microscopic genetic analysis of tissue, manual, initial procedure | Facility | 2023 | 11 | 11 | $2,805 | $358.05 | 12.8% |
| 88369 | Microscopic genetic analysis of tissue, manual, each additional procedure | Facility | 2023 | 11 | 11 | $2,805 | $284.13 | 10.1% |
| 88189 | Flow cytometry technique for dna or cell analysis, 16 or more markers | Facility | 2022 | 138 | 145 | $54,375 | $9,180 | 16.9% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Facility | 2022 | 126 | 269 | $61,870 | $7,731 | 12.5% |
| 88341 | Special stained specimen slides to examine tissue, each additional procedure | Facility | 2022 | 72 | 336 | $45,360 | $7,522 | 16.6% |
| 88319 | Evaluation of specimen enzymes | Facility | 2022 | 120 | 276 | $24,840 | $5,816 | 23.4% |
| 88360 | Microscopic genetic analysis of tumor, manual | Facility | 2022 | 86 | 157 | $31,400 | $5,218 | 16.6% |
| 85097 | Bone marrow, smear interpretation | Facility | 2022 | 120 | 130 | $35,750 | $4,816 | 13.5% |
| 88313 | Special stained specimen slides to examine tissue including interpretation and report | Facility | 2022 | 121 | 355 | $17,750 | $3,412 | 19.2% |
| 88342 | Special stained specimen slides to examine tissue, initial procedure | Facility | 2022 | 85 | 92 | $13,800 | $2,546 | 18.4% |
| 88307 | Pathology examination of tissue using a microscope, moderately high complexity | Facility | 2022 | 32 | 38 | $11,780 | $2,496 | 21.2% |
| 88188 | Flow cytometry technique for dna or cell analysis, 9 to 15 markers | Facility | 2022 | 42 | 47 | $13,160 | $2,307 | 17.5% |
About Dr. Eric Duncavage, MD
Dr. Eric Duncavage, MD is a Anatomic Pathology & Clinical Pathology healthcare provider based in Saint Louis, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/02/2006. The National Provider Identifier (NPI) number assigned to this provider is 1992898688.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Eric Duncavage, MD has received a total of $71,955 in payments from pharmaceutical and medical device companies, with $12,465 received in 2024. These payments were reported across 60 transactions from 13 companies. The most common payment nature is "Consulting Fee" ($51,386).
As a Medicare-enrolled provider, Duncavage has provided services to 4,892 Medicare beneficiaries, totaling 8,137 services with total Medicare billing of $217,616. Data is available for 4 years (2020–2023), covering 62 distinct procedure/service records.
Practice Information
- Specialty Anatomic Pathology & Clinical Pathology
- Location Saint Louis, MO
- Active Since 10/02/2006
- Last Updated 04/17/2025
- Taxonomy Code 207ZP0102X
- Entity Type Individual
- NPI Number 1992898688
Products in Payments
- Reblozyl (Drug) $5,490
- OPDIVO (Biological) $3,717
- Oncology Testing (Device) $3,027
- Genetic Disease Research (Device) $2,946
- TECENTRIQ (Biological) $1,695
- VENCLEXTA (Drug) $525.00
- RealTime BRAF (Device) $378.06
- Vysis ALK (Device) $342.72
- VYXEOS (Drug) $94.12
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Anatomic Pathology & Clinical Pathology Doctors in Saint Louis
Mr. Mohammad Hussaini, Md, MD
Anatomic Pathology & Clinical Pathology — Payments: $69,375
Dr. Jon Ritter, Md, MD
Anatomic Pathology & Clinical Pathology — Payments: $21,625
Dr. Xiuli Liu, Md, MD
Anatomic Pathology & Clinical Pathology — Payments: $16,127
Dr. Adam Booth, Md, MD
Anatomic Pathology & Clinical Pathology — Payments: $15,246
Dr. Elizabeth Brunt, Md, MD
Anatomic Pathology & Clinical Pathology — Payments: $14,889
John Rollo, M.d, M.D
Anatomic Pathology & Clinical Pathology — Payments: $13,480